A double-blind, randomized, placebo-controlled multi-center study to assess the safety and efficacy of AST-120 in mild to moderately active Crohn's patients with fistulas

This study is for mild to moderately active Crohn’s disease patients who have at least one perianal fistula. This study will test the safety and efficacy of the study drug compared to placebo. Participants will receive an eight-week course of study drug or placebo.

To be eligible for this study, you must have mild to moderate Crohn’s disease with at least one fistula that is not currently being treated with infliximab (Remicade). This is a partial statement of eligibility requirements. For more information, or to determine if you are eligible for the study, please call the contact number provided. If you choose to inquire via e-mail, please refer to the title of the study in your message.